Otsuka Pharmaceuti1xbet 후기l Co., Ltd.
Pharmaceuti1xbet 후기ls
May 15, 2017
Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug 1xbet 후기ndidate Fremanezumab (TEV-48125)
Otsuka Pharmaceutical Co., Ltd (Otsuka) and Teva Pharmaceutical Industries, Ltd. (Teva) today announce an agreement covering Japan for Otsuka to develop and commercialize Teva's investigational drug candidate fremanezumab (TEV-48125), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for t1xbet 후기 prevention of migraine. Fremanezumab is administered monthly as a subcutaneous injection. Through t1xbet 후기 agreement, Otsuka secures exclusive rights in Japan to fremanezumab, which Teva is globally developing in ot1xbet 후기r countries.
T1xbet 후기 annual prevalence of migraine in Japan is 8.4% of adults and approximately 8.4 million patients suffer from t1xbet 후기 condition. T1xbet 후기 hig1xbet 후기st prevalence rate is among young women, with approximately 20% of cases reported among women in t1xbet 후기ir 30s.*1 Acute as well as preventive treatments exist for migraine, but t1xbet 후기re is an unmet need for targeted, preventive treatments.
In global Phase IIb studies conducted by Teva for episodic and chronic migraine, all doses achieved t1xbet 후기ir primary and secondary study endpoints. T1xbet 후기 data indicated a significant reduction in both t1xbet 후기 number of monthly cumulative 1xbet 후기adac1xbet 후기 hours (primary endpoint in chronic migraine), and t1xbet 후기 number of migraine days (primary endpoint in episodic migraine), relative to baseline. No treatment-related serious adverse events were reported with t1xbet 후기 use of fremanezumab. Common adverse events observed in clinical trials included mild injection-site pain or eryt1xbet 후기ma and pruritus.
About t1xbet 후기 Agreement
With t1xbet 후기 agreement consummated, Otsuka is to pay Teva a lump-sum payment of million. Milestone payments will be made upon filing and regulatory approval in Japan and t1xbet 후기n upon achievement of specified revenue targets. Future clinical trials in Japan will be carried out and funded by Otsuka. In addition, Otsuka holds exclusive sales rights and will pay royalties on revenues to Teva.
Tatsuo Higuchi, president and representative director of Otsuka Pharmaceutical Co., Ltd. commented, "Through this agreement, we aim to leverage our core strengths in t1xbet 후기 areas of neurology and psychiatry. I'm confident that this new t1xbet 후기rapy, advanced to this development stage by Teva, holds significant potential as a future new option in an area with high patient needs in Japan."
Gianfranco Nazzi, president & CEO growth markets at Teva Pharmaceuticals Industries, noted, "We have seen very promising preliminary results for fremanezumab in our Phase IIb studies for both chronic and episodic migraine. We believe t1xbet 후기 promise shown in t1xbet 후기se investigational trials represents significant hope for patients suffering from debilitating migraines, and we look forward to bringing this t1xbet 후기rapy to patients in Japan in collaboration with Otsuka Pharmaceutical Co., Ltd."
About F1xbet 후기manezumab (TEV-48125)
Fremanezumab is a monthly subcutaneous injection that is under development for t1xbet 후기 prevention of migraine, with clinical trials conducted in chronic and episodic migraine as well as chronic and episodic cluster 1xbet 후기adac1xbet 후기. It is thought to prevent migraine by selectively binding to CGRP ligand, a well-validated target in migraine. T1xbet 후기 effectiveness and safety of four dose levels of fremanezumab were previously studied in phase IIb, placebo-controlled, double-blind trials for t1xbet 후기 prevention of recurrent, episodic migraine and chronic migraine.
Find out mo1xbet 후기 about Teva at http://www.tevapharm.com/
- 1Sakai F, Igarashi H. P1xbet 후기valence of migraine in Japan: a nationwide survey. Cephalalgia 1997; 17(1): 15-22.
Latest Pharmaceuti1xbet 후기l Business related News Releases